Name: NVP-BVU972
Price: 407.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    NVP-BVU972 is a selective and potent inhibitor of c-Met with IC50 of 14 nM. Besides, NVP-BVU972 displays IC50 values more than 1000 nM in other kinases such as the most closely related kinase recepteur d'origine nantais (RON).
    c-Met, also known as hepatocyte growth factor receptor, is a receptor tyrosine kinase that can be activated by hepatocyte growth factor/scatter factor (HGF/SF). It is a membrane protein which plays an essential role in embryonic development and wound healing.
    In the EBC-1, GTL-16, and MKN-45 human cancer cells, NVP-BVU972 potently inhibits the cell proliferation with IC50 values of 82, 66 and 32 nM, respectively. Additionally, NVP-BVU972 treatment leads to the inhibition of the growth of the transformed mouse BaF3 cells containing TPR-MET kinase fusions with IC50 of 104 nM 1.
    In human sample, NVP-BVU972 treatment on cells expressing wild-type TPR-MET resulted in a dose-dependent reduction in TPR-MET phosphorylation. Y1230H, D1228A, F1200I and L1195V mutations abrogate the TPR-MET phosphorylation inhibition effect of NVP-BVU972 in BaF3 TPR-MET1.
- Properties
  - Alternative Name
    
    6-[[6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl]quinoline
    
    CAS Number
    
    1185763-69-2
    
    Molecular Formula
    
    C20H16N6
    
    Molecular Weight
    
    340.38
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; ≥17 mg/mL in DMSO; ≥25.15 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

NVP-BVU972

NVP-BVU972

Background

We Also Recommend

Olsalazine Sodium

Orlistat

Oxeladin Citrate